Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Summary
To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients
Official title: A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2007-07
Completion Date
2008-09
Last Updated
2026-04-21
Healthy Volunteers
No
Conditions
Interventions
Botulinum Toxin Type B (Myobloc)
Matched placebo to Myobloc
Locations (18)
Dr Virgilio Evidente
Scottsdale, Arizona, United States
Dr. Ronald Ziman
Northridge, California, United States
Dr. James Sutton
Oxnard, California, United States
Dr. Olga Klepitskaya
Denver, Colorado, United States
Dr. Fernando Pagan
Washington D.C., District of Columbia, United States
Dr Hubert Fernandez
Gainesville, Florida, United States
Dr. Alan Freeman
Atlanta, Georgia, United States
Dr. Katie Kompoliti
Chicago, Illinois, United States
Dr. Robert Rodnitzky
Iowa City, Iowa, United States
Dr. Stephen Reich
Baltimore, Maryland, United States
Dr. Brad Racette
St Louis, Missouri, United States
Dr. Eric Molho
Albany, New York, United States
Dr. Joseph Friedman
Warwick, Rhode Island, United States
Dr. Vanessa Hinson
Charleston, South Carolina, United States
Dr. Sam Kabbani
Knoxville, Tennessee, United States
Dr. Madhavi Thomas
Dallas, Texas, United States
Dr. Gordon Smith
Salt Lake City, Utah, United States
Dr. Patrick Hogan
Tacoma, Washington, United States